Samsung Biologics Announces KRW 3 Trillion ($2.18B) Rights Offering to Fund PolyPeptide Group Acquisition and Bio Campus II Expansion, Strengthening CDMO Leadership

August 30, 2026

PR Newswire South Korea

Overview

Samsung Biologics has announced a substantial KRW 3 trillion (approximately $2.18 billion) rights offering to finance its acquisition of PolyPeptide Group and the expansion of its Bio Campus II. This strategic capital raise is designed to accelerate the company’s “three-dimensional growth strategy” across production capacity, portfolio, and geographical reach, further solidifying its leadership position in the CDMO sector. The offering marks a critical step to meet surging biopharmaceutical manufacturing demand and establish a competitive edge in the global market.

In Depth

Key Findings

Samsung Biologics has announced a substantial rights offering, totaling KRW 3 trillion (approximately $2.18 billion), to fund its ambitious future expansion plans. This capital will be primarily allocated to the acquisition of PolyPeptide Group, a prominent Swiss peptide manufacturer, and the further expansion of Bio Campus II, a key manufacturing hub for the company. This capital raise represents a crucial strategic decision aimed at strengthening the company’s leadership in the Contract Development and Manufacturing Organization (CDMO) sector and ensuring sustained growth.

Technical / Clinical Details

The acquisition of PolyPeptide Group will extend Samsung Biologics’ service portfolio into the peptide therapeutics domain, complementing its existing biopharmaceutical manufacturing capabilities. Peptide drugs are experiencing growing demand, particularly in areas like diabetes treatment and oncology. This integration will enable the company to address a wider range of client needs. Furthermore, the expansion of Bio Campus II will involve adding state-of-the-art manufacturing facilities and R&D infrastructure, further bolstering production capacity for high-value biopharmaceuticals such as monoclonal antibodies, cell, and gene therapy products. This will enable the company to handle the manufacturing of next-generation biopharmaceuticals with advanced technical requirements.

Background & Context

The global biopharmaceutical market continues to grow rapidly, and the manufacturing of complex biologics requires highly specialized expertise and significant capital investment. Consequently, many pharmaceutical and biotechnology companies are increasingly outsourcing their development and manufacturing processes to CDMOs. Samsung Biologics’ “three-dimensional growth strategy” — expanding production capacity, portfolio, and geographical reach — is designed to actively respond to these market shifts and establish a dominant position in the global CDMO market.

Strategic Significance & Outlook

This rights offering and the accompanying strategic investments represent a pivotal step for Samsung Biologics in solidifying its position as an undisputed leader in the global CDMO market. The integration of PolyPeptide Group will broaden the range of modalities the company offers and diversify its client base. Simultaneously, the expansion of Bio Campus II will reinforce the physical infrastructure needed to meet the increasing demand for biopharmaceutical manufacturing, laying a foundation for long-term growth. Through these efforts, Samsung Biologics will further enhance its role as an indispensable partner in accelerating the market launch of innovative medicines.

Source: https://www.prnewswire.com/news-releases/samsung-biologics-announces-krw-3-trillion-rights-offering-to-fund-its-next-phase-expansion-302862357.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.